The animal study was performed according to the guidelines of the Institutional Animal Care and local veterinary office and ethics committee of the University of Iowa, USA under approved protocol (IACUC 5081482). NOD.Cγ-Rag1 mice 6–8 weeks old (Jackson Laboratory, Bar Harbor, Maine) were injected intravenously with ARP1 MM cells (1 × 106) expressing luciferase. After one-week injection of ARP1 cells, mice were treated with either PAA (4 mg/kg) injected intraperitoneal once a day, 5 days every week for 3 weeks. Melphalan (3 mg/kg) was injected intraperitoneal once a day, 2 days a week for 3 weeks (Sanchez et al., 2012 (link)). Carfilzomib (3 mg/kg) was injected by in vein once a day, 2 days every week for 3 weeks (Eda et al., 2014 (link)). Bortezomib (3 mg/kg) was injected intraperitoneal once a day, 2 days a week for 3 weeks. The mice were euthanized when a humane endpoint was reached.
Nod cγ rag1 mice
Manufactured by Jackson ImmunoResearch
Sourced in United States
NOD.Cγ-Rag1 mice are an immunodeficient mouse model. They lack functional T and B cells, and have impaired innate immunity. These mice can be used for a variety of research applications.
Automatically generated - may contain errors
Lab products found in correlation
3 protocols using nod cγ rag1 mice
1
Evaluating Treatments for Multiple Myeloma
2
Bortezomib Treatment for NOD.Cγ-Rag1 Mice
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
All animal work was performed in accordance with the guidelines of the Institutional Animal Care and Use Committee of the University of Iowa under Animal Study Protocol 1202033. ARP1-ALDH1A1OE cells and ARP1EV cells (1.5 × 106) were injected subcutaneously in the abdominal area of 6–8-week old NOD.Cγ-Rag1 mice (Jackson laboratory, Bar Harbor, Maine). Beginning on day 7 post cell transfer, mice were treated with bortezomib (1 mg/kg IP) twice weekly until humane endpoints were reached. Tumor volume was measured using a caliper and mice were sacrificed by CO2 asphyxiation when tumor diameter reached 20 mm.
3
Murine Multiple Myeloma Cancer Model
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The animal study was performed according to the guidelines of the Institutional Animal Care and local veterinary office and ethics committee of the University of Iowa, USA under approved protocol (IACUC 5081482). NOD.Cγ-Rag1 mice 6–8 weeks old (Jackson Laboratory, Bar Harbor, ME, USA) were injected intravenously or intraperitoneally injection with ARP1 MM cells (1 × 106) expressing luciferase. One-week after injection of ARP1 cells, mice were treated with either PAA (4 mg/kg) intraperitoneally injection once a day, 5 days every week for 3 weeks. DFO (100 mg/kg) was injected intraperitoneally once a day, 2 days a week for 3 weeks. The mice were euthanized when a humane endpoint was reached.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!